title: Hodgkin's lymphoma mortality in the Americas, 1997-2008: achievements and persistent inadequacies.
abstract: Although therapeutic advancements have made Hodgkin's lymphoma (HL) a largely curable disease, trends in HL mortality have been variable across countries. To provide updated information on HL mortality in the Americas, overall and 20-44 years age-standardized (world population) mortality rates from HL were derived for the 12 Latin American countries providing valid data to the World Health Organization database and with more than two million of inhabitants. For comparative purpose, data for the United States and Canada were also presented. Trends in mortality over the 1997 to 2008 period are based on joinpoint regression analysis. Declines in HL mortality were registered in all Latin American countries except in Venezuela. In most recent years, HL mortality had fallen to about 0.3/100,000 men and 0.2/100,000 women in Argentina, Brazil, Chile, Colombia, Ecuador and Guatemala, that is, to values similar to North America. Despite some declines, rates remained high in Cuba (1/100,000 men and 0.7/100,000 women), Costa Rica and Mexico as well as in Venezuela (between 0.5 and 0.6/100,000 men and between 0.3 and 0.5/100,000 women). In young adults, trends were more favorable in all Latin American countries except Cuba, whose rates remained exceedingly high (0.8/100,000 men and 0.6/100,000 women). Thus, appreciable declines in HL mortality were observed in most Latin America over the last decade, and several major countries reached values comparable to North America. Substantial excess mortality was still observed in Cuba, Costa Rica, Mexico and Venezuela, calling for urgent interventions to improve HL management in these countries.
authors: Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. liliane.chatenoud@marionegri.it
authors: Liliane
authors: L
authors: Chatenoud
authors: Paola
authors: P
authors: Bertuccio
authors: Cristina
authors: C
authors: Bosetti
authors: Teresa
authors: T
authors: Rodriguez
authors: Fabio
authors: F
authors: Levi
authors: Eva
authors: E
authors: Negri
authors: Carlo
authors: C
authors: La Vecchia
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002489:Central America / Q000453:epidemiology; D003606:Dacarbazine / Q000627:therapeutic use; D003906:Developing Countries; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality*; D006801:Humans; D008297:Male; D009656:North America / Q000453:epidemiology; D013020:South America / Q000453:epidemiology; D014747:Vinblastine / Q000627:therapeutic use; D014944:World Health Organization; D055815:Young Adult
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin